Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLH-adrenomedullin mRNA vaccine
- Development stage
- Preclinical
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The KLH-adrenomedullin mRNA vaccine is an experimental cancer immunotherapy designed to target adrenomedullin (AM), a regulatory peptide overexpressed in many solid tumors that promotes angiogenesis and tumor growth. The vaccine utilizes in vitro-synthesized mRNA encoding a fusion protein of keyhole limpet hemocyanin (KLH) and adrenomedullin, encapsulated in lipid nanoparticles (LNPs). By acting as a hapten, the KLH component helps break peripheral immunotolerance to the self-antigen adrenomedullin. Administered via intramuscular injection, the vaccine elicits both humoral (anti-AM IgG antibodies) and cellular (CD8+ T cell) immune responses. Preclinical studies in melanoma models have demonstrated its ability to inhibit tumor angiogenesis and reduce tumor volume and metastasis without significant systemic toxicity.
- Other names
- KLH-AM mRNA vaccineKLH-adrenomedullin mRNA-LNP vaccine
02
Targets
ADM (Adrenomedullin)
Beyond the preview
Go deeper on KLH-adrenomedullin mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLH-adrenomedullin mRNA vaccine.